25,729 articles
Pediculosis capitis
Pediculosis capitis, head lice infestation by Pediculus humanus capitis, common in children 3–11, spread by head-to-head contact, treated with pediculicides; pyrethroid resistance now widespread.
Pediculosis corporis
Pediculosis corporis, body lice (Pediculus humanus corporis), is a louse infestation living in clothing and feeding on human blood, causing itching, vagabond's disease, and transmitting typhus, trench fever, and relapsing fever; treated mainly by hygiene and clean clothes.
Pedicure
Pedicure: cosmetic foot and toenail treatment (soaking, nail trimming, cuticle care, massage, polish), from Latin pes + curare. Covers salon procedure, infection risks from foot spas and tools, safety steps, diabetes precautions, and medical pedicures.
Pedigree analysis
Pedigree analysis is a study design in human genetics and epidemiology that examines family trees to infer modes of inheritance, relatedness, and genetic contributions to disease.
PedMASLD-Pilot study
PedMASLD-Pilot (NCT07731360), also called the PedMASLD-MultiOmics Pilot Study, is a not-yet-recruiting observational diagnostic trial at Kayseri City Hospital, Türkiye, testing a LASSO biomarker, elastography, and genetic panel for MASLD in 180 children with obesity aged 8 to 18.
PedNet study
PedNet study: research program of the European Paediatric Network for Haemophilia Management and its PedNet Haemophilia Registry, a prospective birth cohort of children with haemophilia A/B born from 2000, 35 centres in 19 countries, 2,993 children by 2025.
Pedophilic disorder
Pedophilic disorder (ICD-11 6D32) is a paraphilic disorder defined by sustained sexual arousal to prepubertal children, diagnosed only with distress, impairment, or acting on urges; DSM-5 rejected a pedohebephilia revision.
Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome
PLACK syndrome (peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome) is an ultra-rare autosomal recessive genodermatosis caused by CAST loss-of-function variants, first described in 2015, with roughly 19-21 reported cases and a reported dilated cardiomyopathy association.
PEEP titration
PEEP titration is the bedside adjustment of positive end-expiratory pressure to keep alveoli open in ARDS, using methods like PEEP/FiO2 tables, best-compliance trials, and EIT.
PEEP trial (NCT05386901)
PEEP trial, NCT05386901, a registered randomized controlled trial testing lung dynamic compliance-guided PEEP titration versus conventional PEEP to reduce postoperative pulmonary complications in children undergoing video-assisted thoracoscopic surgery with one-lung ventilation.
Pefcalcitol
Pefcalcitol (M518101, M5181) is Maruho's topical vitamin D3 analog and VDR agonist ointment for plaque psoriasis and palmoplantar keratoderma; it reached phase 3 trials, beat vehicle but missed non-inferiority versus calcipotriol, and development was discontinued without approval.
Peficitinib
Peficitinib (ASP015K, JNJ-54781532, Smyraf) is Astellas' oral pan-JAK inhibitor approved in Japan (2019) and Korea (2020) for rheumatoid arthritis, dosed 150 mg once daily, with JAK3 IC50 of 0.7 nM.
Pegademase bovine
Pegademase bovine (Adagen, PEG-ADA) is a PEGylated bovine intestinal adenosine deaminase enzyme replacement therapy for ADA-deficient SCID, FDA-approved March 21, 1990, discontinued 2019 after replacement by elapegademase (Revcovi).
Pegadricase
Pegadricase (SEL-037, pegsiticase) is a PEGylated Candida utilis uricase for refractory gout, paired with rapamycin nanoparticle ImmTOR as SEL-212; monthly dosing matched pegloticase in the COMPARE phase 2 trial.
Pegargiminase
Pegargiminase (ADI-PEG 20, pegylated arginine deiminase), Polaris Pharmaceuticals' PEGylated bacterial enzyme that depletes blood arginine to kill ASS1-deficient cancers; positive phase 3 ATOMIC-Meso trial in mesothelioma, trials in HCC, melanoma, sarcoma.
Pegaspargase
Pegaspargase (Oncaspar, PEG-asparaginase) is a PEGylated E. coli L-asparaginase for acute lymphoblastic leukemia, first FDA-approved 1994, dosed 2,500 IU/m2 every 14 days, with a 5.5-day half-life and lower hypersensitivity than native asparaginase.
PEGASUS trial
PEGASUS trial: name shared by several clinical trials, chiefly PEGASUS-TIMI 54 (NCT01225562), a 21,162-patient AstraZeneca/TIMI trial of ticagrelor 60 or 90 mg twice daily plus aspirin after myocardial infarction, and a phase 3 pegcetacoplan-versus-eculizumab trial in paroxysmal nocturnal hemoglobinuria.
Pegcetacoplan
Pegcetacoplan (Empaveli, Syfovre) is a PEGylated C3/C3b complement inhibitor by Apellis. Approved 2021 for PNH and 2023 as the first FDA-approved drug for geographic atrophy; phase 3 VALIANT showed 68.1% proteinuria reduction in C3 glomerulopathy.
Pegfilgrastim
Pegfilgrastim (Neulasta) is a PEGylated long-acting G-CSF, filgrastim with a 20-kDa PEG chain, FDA-approved January 31, 2002 to prevent febrile neutropenia; given as 6 mg once per chemotherapy cycle, cleared by neutrophils, with multiple biosimilars.
Pegilodecakin
Pegilodecakin, known by the development codes AM0010 and LY3500518, is a PEGylated interleukin-10 drug investigated as a cancer immunotherapy that reached phase 3 testing but was never approved.
Peginesatide
Peginesatide (Omontys), a once-monthly peptide-based erythropoiesis-stimulating agent for anemia in dialysis patients, was FDA-approved in 2012 and recalled in February 2013 after fatal anaphylaxis reactions.
Peginterferon alfa-2a
Peginterferon alfa-2a (Pegasys, PEG-IFN alfa-2a) is a PEGylated recombinant interferon alfa-2a approved in 2002 for chronic hepatitis B and C and later for polycythaemia vera and essential thrombocythaemia, given weekly by subcutaneous injection.
Peginterferon alfa-2b
Peginterferon alfa-2b (PegIntron, Sylatron) is a 12 kDa linear PEG conjugate of interferon alfa-2b, once-weekly injected for chronic hepatitis C and melanoma; EU marketing withdrawn in 2021.
Peginterferon alfa-2b, Y-shaped 40 kDa (Pegbing)
Pegbing (派格宾) is Xiamen Amoytop's 40 kDa Y-shaped pegylated interferon alfa-2b, China's first domestically developed long-acting interferon, approved 2016; 180 μg weekly; non-inferior to peginterferon alfa-2a in HBeAg-positive hepatitis B.
Peginterferon beta-1a
Peginterferon beta-1a (Plegridy, Biogen) is a 20 kDa PEG-conjugated interferon beta-1a for relapsing-remitting multiple sclerosis, given 125 mcg subcutaneously every 2 weeks; FDA and EU approved in 2014.
Peginterferon lambda-1a
Peginterferon lambda-1a (Lambda, PEG-IFN-λ1a) is a pegylated type III interferon developed at ZymoGenetics for chronic hepatitis C; better tolerated than alfa interferons but failed Phase 3 noninferiority and showed no COVID-19 benefit.
Pegloticase
Pegloticase, marketed as Krystexxa, is a PEGylated uricase enzyme given by intravenous infusion every two weeks to lower urate in adults with gout refractory to oral therapy.
Pegmolesatide
Pegmolesatide (培莫沙肽, Saint Luolai) is Hansoh Pharma's once-monthly PEGylated erythropoietin-mimetic peptide for renal anemia, approved by China's NMPA in June 2023 and non-inferior to epoetin alfa in phase 3 trials.
Pegnivacogin
Pegnivacogin (RB006, Revolixys, DTRI-178) is a PEGylated 31-mer RNA aptamer inhibiting factor IXa, paired with the antidote anivamersen in the REG1 anticoagulation system; halted in phase 3 after allergic reactions.
Pegozafermin
Pegozafermin (BIO89-100), a glycoPEGylated FGF21 analog by 89bio, now Roche, treats MASH and severe hypertriglyceridemia; ENLIVEN phase 2b showed fibrosis improvement and NASH resolution.